Shinpoong Pharmaceutical (019170 KS) management is accused of raising KRW 25 billion in slush funds. If found guilty, the shares may be suspended to trade in the stock exchange.
The company’s oral COVID-19 drug is in phase 3 trial. However, late entry and uncertainty over the efficacy of multiple variants of the COVID are dampening sentiment.
Shinpoong Pharmaceutical is investing heavily in R&D to build-up a rich pipeline, which will pressurize profit in near-term.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.